Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
1. FIELD
Provided herein are compositions and methods for the treatment of IRIS by administering to a patient in need thereof an effective amount of a PDE4 modulator described herein.
2. BACKGROUND
One goal of antiretroviral therapy (ART) in immunocompromised HIV-infected individuals is immune
Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
SEQUENCE LISTING SUBMISSION VIA EFS-WEB
A computer readable text file, entitled "067802-5030_SequenceListing.txt," created on or about 10 Apr. 2013, with a file size of about 62 kb contains the sequence listing for this application and is hereby incorporated by reference in its entirety.
The present
Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
BACKGROUND
Renal ischemia-reperfusion injury (IRI) is a major cause of acute kidney injury (AKI) in many clinical settings including cardiovascular surgery, sepsis, and kidney transplantation. Ischemic AKI is associated with increased morbidity, mortality, and prolonged hospitalization (1, 2).
Acute
Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
RELATED APPLICATIONS
This application is a 35 U.S.C. 371 national stage filing of International Application No. PCT/EP2012/064445, filed on Jul. 23, 2012, which claims priority to European Patent Application No. 11006031.6, filed on Jul. 22, 2011. The contents of the aforementioned applications are
Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
SEQUENCE LISTING
The present application is being filed along with a sequence listing in electronic format. The sequence listing is provided as a file entitled, "VLX0001-201-US 20131212 SequenceListing_ST25", created on Dec. 11, 2013 which is 90 Kb in size. The information in the electronic format
Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
SEQUENCE LISTING
The present application is being filed along with a sequence listing in electronic format. The sequence listing is provided as a file entitled, "VLX0001-201-US 20131212 SequenceListing_ST25", created on Dec. 11, 2013 which is 90 Kb in size. The information in the electronic format
Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
SEQUENCE LISTING
The present application is being filed along with a sequence listing in electronic format. The sequence listing is provided as a file entitled, "VLX0001-201-US 20131212 SequenceListing_ST25", created on Dec. 11, 2013 which is 90 Kb in size. The information in the electronic format
Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
The present invention relates to antibodies that bind CD47 and their use in treating conditions and disorders, such as ischemia-reperfusion injury (IRI) and cancers, mediated by this receptor.
CD47 is a cell surface receptor comprised of an extracellular IgV set domain, a 5 membrane spanning
Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
INCORPORATION OF SEQUENCE LISTING
The present application is being filed along with a Sequence Listing in electronic format. The Sequence Listing is provided as a file entitled, "VLX0001-201CIP2 US_SequenceListing", created on Jun. 11, 2015, which is 168,755 bytes in size. The information in the
Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
BACKGROUND
The present disclosure relates to antibodies that bind CD47, including that of humans and other mammalian species, and their use in treating conditions and disorders, such as ischemia-reperfusion injury (IRI) and cancers, mediated by this receptor.
CD47 is a cell surface receptor
Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
TECHNICAL FIELD
The present invention relates to novel cyclic compounds having a Toll-like receptor 4 (TLR4) signal inhibitory action useful as preventive and therapeutic drugs of autoimmune disease and/or inflammatory disease or diseases such as chemotherapy-induced peripheral neuropathy (CIPN),
Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
TECHNICAL FIELD
The present invention relates to novel cyclic compounds having a Toll-like receptor 4 (TLR4) signal inhibitory action useful as preventive and therapeutic drugs of autoimmune disease and/or inflammatory disease or diseases such as chemotherapy-induced peripheral neuropathy (CIPN),
Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
BACKGROUND OF THE INVENTION
Ischemia-reperfusion injury (IRI) involving harvested organs and allograft transplantation may in part be caused by stimulation of a newly described innate pro-inflammatory immune system (i.e. cryopyrin-inflammasome, now referred to as NLRP-3 or NALP-3 inflammasome) that
Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
BACKGROUND OF THE INVENTION
1. Field of the Invention
The invention relates to an ultrapure, high molecular weight hyaluronic acid, generally, but not necessarily in the form of the sodium salt (hereinafter referred to as "HUA"), obtained from animal connective tissue such as rooster combs, human
Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention pertains to a non-primate vitreal replacement process that quantitates the inflammatory response to viscoelastic agents or solutions.
2. Description of the Prior Art
The owl monkey (Aotus trivigatus) was used as a process
La base de datos de hierbas medicinales más completa respaldada por la ciencia
Funciona en 55 idiomas
Curas a base de hierbas respaldadas por la ciencia
Reconocimiento de hierbas por imagen
Mapa GPS interactivo: etiquete hierbas en la ubicación (próximamente)
Leer publicaciones científicas relacionadas con su búsqueda
Buscar hierbas medicinales por sus efectos.
Organice sus intereses y manténgase al día con las noticias de investigación, ensayos clínicos y patentes.
Escriba un síntoma o una enfermedad y lea acerca de las hierbas que podrían ayudar, escriba una hierba y vea las enfermedades y los síntomas contra los que se usa. * Toda la información se basa en investigaciones científicas publicadas.